首页 > 最新文献

Current Opinion in Cardiology最新文献

英文 中文
No-touch saphenous vein: current understanding of the conduit 'less handled'. 无触点隐静脉:目前对 "少处理 "导管的理解。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-04-05 DOI: 10.1097/hco.0000000000001149
Mimi X Deng, Grace S Lee, Dominique Vervoort, Stephen E Fremes
The no-touch technique is an established method to harvest the saphenous vein (NT-SV), which is the most commonly used conduit in coronary artery bypass grafting. Herein, we summarize the foundational evidence, as well as highlight recent innovations and ongoing clinical trials involving NT-SV.
无接触技术是一种成熟的采集大隐静脉(NT-SV)的方法,而大隐静脉是冠状动脉旁路移植术中最常用的导管。在此,我们总结了基础证据,并重点介绍了涉及 NT-SV 的最新创新和正在进行的临床试验。
{"title":"No-touch saphenous vein: current understanding of the conduit 'less handled'.","authors":"Mimi X Deng, Grace S Lee, Dominique Vervoort, Stephen E Fremes","doi":"10.1097/hco.0000000000001149","DOIUrl":"https://doi.org/10.1097/hco.0000000000001149","url":null,"abstract":"The no-touch technique is an established method to harvest the saphenous vein (NT-SV), which is the most commonly used conduit in coronary artery bypass grafting. Herein, we summarize the foundational evidence, as well as highlight recent innovations and ongoing clinical trials involving NT-SV.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":"49 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controversies related to renal artery denervation and devices. 与肾动脉去神经化和设备有关的争议。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-04-04 DOI: 10.1097/hco.0000000000001146
Chibuike Charles Agwuegbo, Akanimo Usen Antia, Garba Rimamskep Shamaki, Tamunoinemi Bob-Manuel
This review article discusses the controversies, strengths, and limitations of the current literature on renal artery denervation in the management of resistant hypertension, as well as the future directions of this intervention.
这篇综述文章讨论了目前关于肾动脉去神经化治疗耐药性高血压的文献中存在的争议、优势和局限性,以及这种干预方法的未来发展方向。
{"title":"Controversies related to renal artery denervation and devices.","authors":"Chibuike Charles Agwuegbo, Akanimo Usen Antia, Garba Rimamskep Shamaki, Tamunoinemi Bob-Manuel","doi":"10.1097/hco.0000000000001146","DOIUrl":"https://doi.org/10.1097/hco.0000000000001146","url":null,"abstract":"This review article discusses the controversies, strengths, and limitations of the current literature on renal artery denervation in the management of resistant hypertension, as well as the future directions of this intervention.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":"67 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention and treatment of hypertensive left ventricular hypertrophy. 预防和治疗高血压左心室肥厚。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-05 DOI: 10.1097/hco.0000000000001135
Manvita Tatavarthy, John Stathopoulos, Ahmet Afşin Oktay
Left ventricular (LV) hypertrophy (LVH) is a well recognized target organ adaptation to longstanding uncontrolled hypertension and other cardiovascular risk factors. It is also a strong and independent predictor of many cardiovascular disorders.
左心室肥厚(LVH)是公认的适应长期不受控制的高血压和其他心血管风险因素的靶器官。它也是许多心血管疾病的一个强有力的独立预测因子。
{"title":"Prevention and treatment of hypertensive left ventricular hypertrophy.","authors":"Manvita Tatavarthy, John Stathopoulos, Ahmet Afşin Oktay","doi":"10.1097/hco.0000000000001135","DOIUrl":"https://doi.org/10.1097/hco.0000000000001135","url":null,"abstract":"Left ventricular (LV) hypertrophy (LVH) is a well recognized target organ adaptation to longstanding uncontrolled hypertension and other cardiovascular risk factors. It is also a strong and independent predictor of many cardiovascular disorders.","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":"42 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140576504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart transplant donation after circulatory death: current status and implications. 循环死亡后的心脏移植捐赠:现状与影响。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2023-12-18 DOI: 10.1097/HCO.0000000000001109
Savitri Fedson

Purpose of review: The use of cardiac transplantation following circulatory death (DCD) has been limited worldwide. Concerns about cardiac function after warm ischemia and the potential for decreased graft function have been important considerations in this hesitancy. In addition, ethical and legal questions about the two widely used organ procurement methods have led to discussions and public education in many countries.

Recent findings: Publication of a US randomized trial of cardiac transplantation following DCD has shown that it is both feasible and has similar short-term outcomes compared with cardiac transplantation following brain death (DBD). These data support those from both Australia and the UK who have largest experience to date.

Summary: The adoption of cardiac transplantation following circulatory death has increased overall cardiac transplantation in those transplant centers who have incorporated these donors. Short term outcomes for DCD organ procurement methods are similar to those outcomes using DBD hearts. Continued study and standardization of warm ischemic times will allow for better comparisons of organ procurement techniques and organ optimization. The ethical concerns about procurement methods, in addition to a discussion of procurement costs and feasibility will need to be addressed further in the efforts to expand the organ pool and increase overall cardiac transplantation numbers.

审查目的:在全球范围内,循环死亡(DCD)后心脏移植的使用一直受到限制。人们对热缺血后心脏功能的担忧以及移植物功能下降的可能性是造成这种犹豫不决的重要原因。此外,有关两种广泛使用的器官获取方法的伦理和法律问题也引发了许多国家的讨论和公众教育:美国公布的一项关于 DCD 后心脏移植的随机试验表明,与脑死亡(DBD)后心脏移植相比,DCD 后心脏移植是可行的,并且具有相似的短期效果。这些数据支持了澳大利亚和英国迄今为止最丰富的经验。摘要:循环死亡后心脏移植的采用增加了那些纳入这些供体的移植中心的整体心脏移植量。DCD器官获取方法的短期结果与使用DBD心脏的结果相似。对温暖缺血时间的持续研究和标准化将有助于更好地比较器官获取技术和器官优化。在努力扩大器官库和增加整体心脏移植数量的过程中,除了讨论器官获取成本和可行性外,还需要进一步解决有关器官获取方法的伦理问题。
{"title":"Heart transplant donation after circulatory death: current status and implications.","authors":"Savitri Fedson","doi":"10.1097/HCO.0000000000001109","DOIUrl":"10.1097/HCO.0000000000001109","url":null,"abstract":"<p><strong>Purpose of review: </strong>The use of cardiac transplantation following circulatory death (DCD) has been limited worldwide. Concerns about cardiac function after warm ischemia and the potential for decreased graft function have been important considerations in this hesitancy. In addition, ethical and legal questions about the two widely used organ procurement methods have led to discussions and public education in many countries.</p><p><strong>Recent findings: </strong>Publication of a US randomized trial of cardiac transplantation following DCD has shown that it is both feasible and has similar short-term outcomes compared with cardiac transplantation following brain death (DBD). These data support those from both Australia and the UK who have largest experience to date.</p><p><strong>Summary: </strong>The adoption of cardiac transplantation following circulatory death has increased overall cardiac transplantation in those transplant centers who have incorporated these donors. Short term outcomes for DCD organ procurement methods are similar to those outcomes using DBD hearts. Continued study and standardization of warm ischemic times will allow for better comparisons of organ procurement techniques and organ optimization. The ethical concerns about procurement methods, in addition to a discussion of procurement costs and feasibility will need to be addressed further in the efforts to expand the organ pool and increase overall cardiac transplantation numbers.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"128-134"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Worsening heart failure: a concept in evolution. 心力衰竭恶化:演变中的概念。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2023-12-18 DOI: 10.1097/HCO.0000000000001108
Max Puthenpura, Jennifer Wilcox, W H Wilson Tang

Purpose of review: Worsening heart failure (WHF) has developed as a unique definition within heart failure (HF) in recent years. It captures the disease as a dynamic process. This review describes what is currently known about WHF, why it should be considered a discrete scientific endpoint, and future directions for research.

Recent findings: There is no single agreed upon definition for WHF. It can be identified as being due to treatment side-effects, related to concomitant comorbidity, or true disease progression. Risk scores based on criteria like those already developed for HF can be created to stratify risk for WHF.

Conclusions: WHF is an emerging entity within HF that defines itself as a unique point of interest. Understanding it as a clinical measure of where a patient's HF is evolving allows for identifying patients that require a refreshed approach to their care. Keeping this in mind will help redefine more patient-centric outcome measures in research to come.

综述目的:近年来,恶化型心力衰竭(WHF)已发展成为心力衰竭(HF)中的一个独特定义。它将疾病视为一个动态过程。本综述介绍了目前对WHF的了解、为何应将其视为一个独立的科学终点以及未来的研究方向:WHF目前尚无统一的定义。它可以被认定为是由于治疗副作用、并发症或真正的疾病进展所致。可根据已为高血压制定的标准创建风险评分,对 WHF 进行风险分层:WHF是心房颤动中的一个新兴实体,它将自身定义为一个独特的关注点。将其理解为衡量患者高房颤动发展情况的临床指标,有助于识别需要重新护理的患者。牢记这一点将有助于在今后的研究中重新定义更多以患者为中心的结果测量。
{"title":"Worsening heart failure: a concept in evolution.","authors":"Max Puthenpura, Jennifer Wilcox, W H Wilson Tang","doi":"10.1097/HCO.0000000000001108","DOIUrl":"10.1097/HCO.0000000000001108","url":null,"abstract":"<p><strong>Purpose of review: </strong>Worsening heart failure (WHF) has developed as a unique definition within heart failure (HF) in recent years. It captures the disease as a dynamic process. This review describes what is currently known about WHF, why it should be considered a discrete scientific endpoint, and future directions for research.</p><p><strong>Recent findings: </strong>There is no single agreed upon definition for WHF. It can be identified as being due to treatment side-effects, related to concomitant comorbidity, or true disease progression. Risk scores based on criteria like those already developed for HF can be created to stratify risk for WHF.</p><p><strong>Conclusions: </strong>WHF is an emerging entity within HF that defines itself as a unique point of interest. Understanding it as a clinical measure of where a patient's HF is evolving allows for identifying patients that require a refreshed approach to their care. Keeping this in mind will help redefine more patient-centric outcome measures in research to come.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"119-127"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials. 肥胖/心脏代谢表型的射血分数持续性心力衰竭:近期试验的机制。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2024-01-25 DOI: 10.1097/HCO.0000000000001113
Raj Verma, Nitish K Dhingra, Kim A Connelly

Purpose of review: Heart failure with preserved ejection fraction (HFpEF) is a leading and growing cause of morbidity and mortality globally. Of the various phenotypes identified, the obesity (or cardiometabolic) phenotype appears to be most common. The purpose of this review is to provide the clinician with an abridged understanding of recent developments that have elucidated obesity/visceral adiposity as a central mechanism linking inflammation/immune dysregulation to the development of the HFpEF syndrome. Recent clinical trials examining the efficacy of pharmacological treatments that target obesity in HFpEF will also be discussed.

Recent findings: Recent data indicate that visceral adiposity and insulin resistance in HFpEF serve as key mechanisms driving inflammation and immune dysregulation, which play a critical role in the development of cardiac stiffness, diastolic dysfunction and fibrosis in HFpEF. In obesity, alterations in macrophage polarization, changes in innate and adaptive immune systems and altered myocardial energetics promote metabolic inflammation in HFpEF. Finally, emerging data suggest that inflammatory biomarkers, specifically, IL-6, may provide useful information about HFpEF severity and symptom burden in obesity.

Summary: The obesity phenotype of HFpEF is seen in upward of 80% with HFpEF. Obesity is not just a bystander, but plays an essential role in the pathobiology and clinical course of HFpEF. Targeting overweight/obesity in HFpEF with GLP-1 receptor agonists holds promise in these patients.

综述目的:射血分数保留型心力衰竭(HFpEF)是导致全球发病率和死亡率的主要原因,而且发病率和死亡率还在不断上升。在已发现的各种表型中,肥胖(或心脏代谢)表型似乎最为常见。本综述旨在向临床医生简要介绍近期的研究进展,阐明肥胖/内脏脂肪过多是炎症/免疫调节失调与心房颤动综合征发病之间的核心机制。此外,还将讨论最近的临床试验,这些试验研究了针对肥胖症的药物治疗对 HFpEF 的疗效:最近的数据表明,HFpEF 中的内脏脂肪和胰岛素抵抗是驱动炎症和免疫失调的关键机制,而炎症和免疫失调在 HFpEF 心脏僵硬、舒张功能障碍和纤维化的发展过程中起着至关重要的作用。在肥胖症患者中,巨噬细胞极化的改变、先天性和适应性免疫系统的改变以及心肌能量的改变会促进 HFpEF 的代谢性炎症。最后,新出现的数据表明,炎症生物标志物,特别是 IL-6,可提供有关肥胖症 HFpEF 严重程度和症状负担的有用信息。肥胖不仅是旁观者,而且在 HFpEF 的病理生物学和临床过程中起着至关重要的作用。使用 GLP-1 受体激动剂治疗 HFpEF 中的超重/肥胖症有望治愈这些患者。
{"title":"Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials.","authors":"Raj Verma, Nitish K Dhingra, Kim A Connelly","doi":"10.1097/HCO.0000000000001113","DOIUrl":"10.1097/HCO.0000000000001113","url":null,"abstract":"<p><strong>Purpose of review: </strong>Heart failure with preserved ejection fraction (HFpEF) is a leading and growing cause of morbidity and mortality globally. Of the various phenotypes identified, the obesity (or cardiometabolic) phenotype appears to be most common. The purpose of this review is to provide the clinician with an abridged understanding of recent developments that have elucidated obesity/visceral adiposity as a central mechanism linking inflammation/immune dysregulation to the development of the HFpEF syndrome. Recent clinical trials examining the efficacy of pharmacological treatments that target obesity in HFpEF will also be discussed.</p><p><strong>Recent findings: </strong>Recent data indicate that visceral adiposity and insulin resistance in HFpEF serve as key mechanisms driving inflammation and immune dysregulation, which play a critical role in the development of cardiac stiffness, diastolic dysfunction and fibrosis in HFpEF. In obesity, alterations in macrophage polarization, changes in innate and adaptive immune systems and altered myocardial energetics promote metabolic inflammation in HFpEF. Finally, emerging data suggest that inflammatory biomarkers, specifically, IL-6, may provide useful information about HFpEF severity and symptom burden in obesity.</p><p><strong>Summary: </strong>The obesity phenotype of HFpEF is seen in upward of 80% with HFpEF. Obesity is not just a bystander, but plays an essential role in the pathobiology and clinical course of HFpEF. Targeting overweight/obesity in HFpEF with GLP-1 receptor agonists holds promise in these patients.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"92-97"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations & challenges of mitral valve repair in females: diagnosis, pathology, and intervention. 女性二尖瓣修复的注意事项和挑战:诊断、病理和干预。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1097/HCO.0000000000001107
Mimi Xiaoming Deng, Batol Barodi, Malak Elbatarny, Terrence M Yau

Purpose of review: Disparities in mitral valve (MV) repair outcomes exist between men and women. This review highlights sex-specific differences in MV disease aetiology, diagnosis, as well as timing and type of intervention.

Recent findings: Females present with more complicated disease: anterior or bileaflet prolapse, leaflet dysplasia/thickening, mitral annular calcification, and mixed mitral lesions. The absence of indexed echocardiographic mitral regurgitation (MR) severity parameters contributes to delayed intervention in women, resulting in more severe symptom burden at time of surgery. The sequelae of chronic MR also necessitate concomitant procedures (e.g. tricuspid repair, arrhythmia surgery) at the time of mitral surgery. Complex MV pathology, greater patient acuity, and more complicated procedures collectively pose challenges to successful MV repair and postoperative recovery. As a consequence, women receive disproportionately more MV replacement than men. In-hospital mortality after MV repair is also greater in women than men. Long-term outcomes of MV repair are comparable after risk-adjustment for preoperative status; however, women experience a greater incidence of postoperative heart failure.

Summary: To address the inequity in MV repair outcomes between sexes, indexed diagnostic measurements, diligent surveillance of asymptomatic MR, increased recruitment of women in large clinical trials, and mandatory reporting of sex-based subgroup analyses are recommended.

审查目的:男性和女性在二尖瓣修复结果方面存在差异。本综述强调了二尖瓣疾病的病因、诊断以及介入治疗的时机和类型方面的性别差异:最新发现:女性的疾病更为复杂:前部或双叶脱垂、瓣叶发育不良/增厚、二尖瓣环钙化以及混合性二尖瓣病变。由于缺乏超声心动图二尖瓣反流(MR)严重程度的指数参数,导致女性患者的介入治疗被延迟,从而在手术时出现更严重的症状。慢性二尖瓣反流的后遗症还要求在进行二尖瓣手术时同时进行其他手术(如三尖瓣修复术、心律失常手术)。复杂的中上心房病理、更高的患者敏锐度以及更复杂的手术共同为中上心房修复手术的成功和术后恢复带来了挑战。因此,女性接受中风置换术的比例高于男性。女性中风修补术后的院内死亡率也高于男性。总结:为解决中风修复术后男女不平等的问题,建议进行指数化诊断测量、对无症状 MR 进行严格监测、在大型临床试验中招募更多女性、强制报告基于性别的亚组分析。
{"title":"Considerations & challenges of mitral valve repair in females: diagnosis, pathology, and intervention.","authors":"Mimi Xiaoming Deng, Batol Barodi, Malak Elbatarny, Terrence M Yau","doi":"10.1097/HCO.0000000000001107","DOIUrl":"10.1097/HCO.0000000000001107","url":null,"abstract":"<p><strong>Purpose of review: </strong>Disparities in mitral valve (MV) repair outcomes exist between men and women. This review highlights sex-specific differences in MV disease aetiology, diagnosis, as well as timing and type of intervention.</p><p><strong>Recent findings: </strong>Females present with more complicated disease: anterior or bileaflet prolapse, leaflet dysplasia/thickening, mitral annular calcification, and mixed mitral lesions. The absence of indexed echocardiographic mitral regurgitation (MR) severity parameters contributes to delayed intervention in women, resulting in more severe symptom burden at time of surgery. The sequelae of chronic MR also necessitate concomitant procedures (e.g. tricuspid repair, arrhythmia surgery) at the time of mitral surgery. Complex MV pathology, greater patient acuity, and more complicated procedures collectively pose challenges to successful MV repair and postoperative recovery. As a consequence, women receive disproportionately more MV replacement than men. In-hospital mortality after MV repair is also greater in women than men. Long-term outcomes of MV repair are comparable after risk-adjustment for preoperative status; however, women experience a greater incidence of postoperative heart failure.</p><p><strong>Summary: </strong>To address the inequity in MV repair outcomes between sexes, indexed diagnostic measurements, diligent surveillance of asymptomatic MR, increased recruitment of women in large clinical trials, and mandatory reporting of sex-based subgroup analyses are recommended.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"86-91"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wellness and burnout in cardiac surgery: not black and white. 心脏外科的健康与职业倦怠:非黑即白。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2023-12-20 DOI: 10.1097/HCO.0000000000001112
Aliya Izumi, Akachukwu Nwakoby, Raj Verma, Bobby Yanagawa

Purpose of review: Despite a growing emphasis on burnout in medicine, there remains a paucity of data in cardiac surgery. Herein, we summarize recent data on cardiac surgeon well being and identify factors for consideration in future burnout inquiries and management.

Recent findings: Overall, 70-90% of cardiothoracic surgeons report job satisfaction in the United States. However, 35-60% still endorse burnout symptoms, and the specialty reports some of the highest rates of depression (35-40%) and suicidal ideation (7%). Such negative experiences are greater among early-stage and female surgeons and may be addressed through targeted, program-specific wellness policies. Canada's single-payer healthcare system might exacerbate surgeon burnout due to lower financial compensation and job autonomy.

Summary: Cardiothoracic surgeons appear simultaneously burnt out and professionally fulfilled. They report a high incidence of depression and clock in the most hours, yet the majority would choose this specialty again. These findings reveal a more nuanced state of well being than previously appreciated and speak to ambiguities in how burnout is conceived and measured. A broader examination across surgical and social contexts highlights the hierarchical nature of burnout factors and potential ways forward. Collectively, these insights can inform assessments of burnout in Canadian cardiac surgery that remain absent to date.

回顾的目的:尽管医学界越来越重视职业倦怠问题,但有关心脏外科的数据仍然很少。在此,我们总结了有关心脏外科医生健康状况的最新数据,并确定了在未来的职业倦怠调查和管理中需要考虑的因素:总体而言,美国 70-90% 的心胸外科医生对工作表示满意。然而,仍有 35-60% 的心胸外科医生有职业倦怠症状,该专业的抑郁症(35-40%)和自杀倾向(7%)发病率最高。这种负面经历在早期阶段和女性外科医生中更为严重,可以通过有针对性的、针对特定项目的健康政策来解决。由于经济补偿和工作自主权较低,加拿大的单付费医疗系统可能会加剧外科医生的职业倦怠。他们的抑郁症发病率很高,工作时间最长,但大多数人仍愿意再次选择这一专业。这些发现揭示了一种比以往所理解的更为细微的健康状态,同时也说明了如何看待和衡量职业倦怠的模糊性。在外科和社会背景下进行的更广泛的研究突出了职业倦怠因素的等级性质和潜在的前进方向。总之,这些见解可以为加拿大心脏外科倦怠评估提供参考,而迄今为止,加拿大心脏外科仍未开展过此类评估。
{"title":"Wellness and burnout in cardiac surgery: not black and white.","authors":"Aliya Izumi, Akachukwu Nwakoby, Raj Verma, Bobby Yanagawa","doi":"10.1097/HCO.0000000000001112","DOIUrl":"10.1097/HCO.0000000000001112","url":null,"abstract":"<p><strong>Purpose of review: </strong>Despite a growing emphasis on burnout in medicine, there remains a paucity of data in cardiac surgery. Herein, we summarize recent data on cardiac surgeon well being and identify factors for consideration in future burnout inquiries and management.</p><p><strong>Recent findings: </strong>Overall, 70-90% of cardiothoracic surgeons report job satisfaction in the United States. However, 35-60% still endorse burnout symptoms, and the specialty reports some of the highest rates of depression (35-40%) and suicidal ideation (7%). Such negative experiences are greater among early-stage and female surgeons and may be addressed through targeted, program-specific wellness policies. Canada's single-payer healthcare system might exacerbate surgeon burnout due to lower financial compensation and job autonomy.</p><p><strong>Summary: </strong>Cardiothoracic surgeons appear simultaneously burnt out and professionally fulfilled. They report a high incidence of depression and clock in the most hours, yet the majority would choose this specialty again. These findings reveal a more nuanced state of well being than previously appreciated and speak to ambiguities in how burnout is conceived and measured. A broader examination across surgical and social contexts highlights the hierarchical nature of burnout factors and potential ways forward. Collectively, these insights can inform assessments of burnout in Canadian cardiac surgery that remain absent to date.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"98-103"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comprehensive overview of surgical and transcatheter therapies to treat tricuspid regurgitation in patients with heart failure. 全面概述治疗心力衰竭患者三尖瓣反流的手术和经导管疗法。
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2023-12-18 DOI: 10.1097/HCO.0000000000001110
Vincent Chen, Omar Abdul-Jawad Altisent, Rishi Puri

Purpose of review: The unique pathophysiologic considerations of severe tricuspid regurgitation (TR) have led to advancements in surgical and transcatheter treatments. The purpose of this review is to highlight the current surgical and transcatheter tricuspid valve interventions (TTVI) to functional TR.

Recent findings: Surgical repair with ring annuloplasty consistently demonstrates better outcomes than surgical replacement or other repair approaches. However, surgical uptake of TR correction remains relatively low, and operative mortality rates are still high owing to multiple comorbidities and advanced tricuspid valve disease/right ventricular dysfunction at time of referral. Pivotal trials for tricuspid transcatheter edge-to-edge repair (T-TEER) and transcatheter TV replacement (TTVR) indicate improved quality of life compared to medical therapy alone for high-surgical-risk patients with severe symptomatic TR. Trials are underway to assess caval valve implantation (CAVI), which holds hope for many severe TR patients who are not ideal candidates for T-TEER or orthotopic TTVR. Peri-procedural optimization of right ventricular function remains critical to promote both device success and patient outcomes.

Summary: Clinical outcomes after surgical TV intervention are poor, often due to intervening late in the disease course of TR. TTVI covers a treatment gap for patients deemed inoperable or high-surgical-risk, but earlier referral for TV interventions is still important prior to patients developing multiorgan dysfunction from chronic untreated TR.

综述目的:严重三尖瓣反流(TR)的独特病理生理因素促使手术和经导管治疗取得了进展。本综述旨在重点介绍目前针对功能性三尖瓣反流的手术和经导管三尖瓣介入治疗(TTVI):与手术置换或其他修复方法相比,使用环形瓣环成形术进行手术修复的疗效更好。然而,由于转诊时存在多种并发症和晚期三尖瓣疾病/右心室功能障碍,TR矫正手术的接受率仍然相对较低,手术死亡率仍然很高。三尖瓣经导管边缘到边缘修补术(T-TEER)和经导管电视瓣置换术(TTVR)的关键性试验表明,与单纯药物治疗相比,严重症状性 TR 的高手术风险患者的生活质量有所改善。评估腔瓣植入术(CAVI)的试验正在进行中,这为许多不适合接受 T-TEER 或正位 TTVR 的严重 TR 患者带来了希望。手术前优化右心室功能对于提高设备成功率和患者预后仍然至关重要。摘要:外科TV介入治疗后的临床预后不佳,这通常是由于在TR病程中介入较晚所致。TTVI弥补了被认为无法手术或手术风险高的患者的治疗空白,但在患者因长期未治疗TR而出现多器官功能障碍之前,尽早转诊进行TV介入治疗仍然非常重要。
{"title":"A comprehensive overview of surgical and transcatheter therapies to treat tricuspid regurgitation in patients with heart failure.","authors":"Vincent Chen, Omar Abdul-Jawad Altisent, Rishi Puri","doi":"10.1097/HCO.0000000000001110","DOIUrl":"10.1097/HCO.0000000000001110","url":null,"abstract":"<p><strong>Purpose of review: </strong>The unique pathophysiologic considerations of severe tricuspid regurgitation (TR) have led to advancements in surgical and transcatheter treatments. The purpose of this review is to highlight the current surgical and transcatheter tricuspid valve interventions (TTVI) to functional TR.</p><p><strong>Recent findings: </strong>Surgical repair with ring annuloplasty consistently demonstrates better outcomes than surgical replacement or other repair approaches. However, surgical uptake of TR correction remains relatively low, and operative mortality rates are still high owing to multiple comorbidities and advanced tricuspid valve disease/right ventricular dysfunction at time of referral. Pivotal trials for tricuspid transcatheter edge-to-edge repair (T-TEER) and transcatheter TV replacement (TTVR) indicate improved quality of life compared to medical therapy alone for high-surgical-risk patients with severe symptomatic TR. Trials are underway to assess caval valve implantation (CAVI), which holds hope for many severe TR patients who are not ideal candidates for T-TEER or orthotopic TTVR. Peri-procedural optimization of right ventricular function remains critical to promote both device success and patient outcomes.</p><p><strong>Summary: </strong>Clinical outcomes after surgical TV intervention are poor, often due to intervening late in the disease course of TR. TTVI covers a treatment gap for patients deemed inoperable or high-surgical-risk, but earlier referral for TV interventions is still important prior to patients developing multiorgan dysfunction from chronic untreated TR.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"110-118"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which lesions are not amenable to tricuspid clipping? 哪些病变不能进行三尖瓣修剪?
IF 2.3 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-03-01 Epub Date: 2023-11-29 DOI: 10.1097/HCO.0000000000001105
Shahrukh N Bakar, Neil P Fam

Purpose of review: Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a well tolerated and effective therapeutic option for many patients with symptomatic severe tricuspid regurgitation at prohibitive surgical risk. However, there remain several important limitations to clip-based technology in the context of other rapidly emerging percutaneous treatment options for tricuspid regurgitation.

Recent findings: Tricuspid lesions pose unique challenges to treatment with the current toolbox of transcatheter clip-based technologies. This review will explore key issues related to patient factors, anatomical factors, and imaging factors that may render lesions to be unsuitable for treatment with T-TEER.

Summary: Selection for T-TEER must include a detailed clinical evaluation in the context of a 'heart team' approach involving multiple subspecialists, with screening for patient/lesion characteristics that make T-TEER suboptimal with current clip-based technologies. Future directions for research include patient-specific 3D modeling techniques, leaflet grasping techniques, clip deployment strategies, and personalized device sizing to increase the spectrum of lesions that may be treated with T-TEER within the context of other emerging transcatheter treatment options.

综述目的:三尖瓣经导管边缘到边缘修补术(T-TEER)已成为一种耐受性良好且有效的治疗方法,适用于许多有症状且手术风险过高的严重三尖瓣反流患者。然而,与其他迅速兴起的三尖瓣反流经皮治疗方案相比,夹式技术仍存在一些重要的局限性:三尖瓣病变给目前的经导管夹式技术治疗带来了独特的挑战。本综述将探讨与患者因素、解剖因素和成像因素有关的关键问题,这些因素可能会导致病变不适合用 T-TEER 治疗。摘要:T-TEER 的选择必须包括在 "心脏团队 "方法的背景下进行详细的临床评估,该方法涉及多个亚专科医生,并筛查患者/病变特征,这些特征使 T-TEER 成为目前基于夹子的技术的次优选择。未来的研究方向包括患者特异性三维建模技术、瓣叶抓取技术、夹子部署策略和个性化设备尺寸,以便在其他新兴经导管治疗方案的背景下,扩大 T-TEER 治疗病变的范围。
{"title":"Which lesions are not amenable to tricuspid clipping?","authors":"Shahrukh N Bakar, Neil P Fam","doi":"10.1097/HCO.0000000000001105","DOIUrl":"10.1097/HCO.0000000000001105","url":null,"abstract":"<p><strong>Purpose of review: </strong>Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a well tolerated and effective therapeutic option for many patients with symptomatic severe tricuspid regurgitation at prohibitive surgical risk. However, there remain several important limitations to clip-based technology in the context of other rapidly emerging percutaneous treatment options for tricuspid regurgitation.</p><p><strong>Recent findings: </strong>Tricuspid lesions pose unique challenges to treatment with the current toolbox of transcatheter clip-based technologies. This review will explore key issues related to patient factors, anatomical factors, and imaging factors that may render lesions to be unsuitable for treatment with T-TEER.</p><p><strong>Summary: </strong>Selection for T-TEER must include a detailed clinical evaluation in the context of a 'heart team' approach involving multiple subspecialists, with screening for patient/lesion characteristics that make T-TEER suboptimal with current clip-based technologies. Future directions for research include patient-specific 3D modeling techniques, leaflet grasping techniques, clip deployment strategies, and personalized device sizing to increase the spectrum of lesions that may be treated with T-TEER within the context of other emerging transcatheter treatment options.</p>","PeriodicalId":55197,"journal":{"name":"Current Opinion in Cardiology","volume":" ","pages":"79-85"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1